Inês Alves has a degree in veterinary medicine, Oporto University; a post-graduation in soft tissues surgery – Lusofona University, and is a Ph.D. student, in Human Kinetics – Évora University, Portugal. Her advocacy involvement in rare bone conditions started after becoming mother of a child with achondroplasia in 2012. She is member of the Committee for Orphan Medicinal Products (COMP) at the European Medicine Agency; European Patient Advocacy groups (ePAG) representative at the European Reference Network for Rare Bone diseases – ERN BOND; founder and president of ANDO Portugal, the Skeletal Dysplasia National Association; co-leader of the Patient Outcomes at the European Registry for Rare bone and Mineral conditions (EuRR-Bone); EUPATI fellow and EUPATI Portugal vice-President; founder and first chair of the European Rare Bone Forum (ERBF); co-leader of the Translational Outreach working group of GEMSTONE COST action; member of EURORDIS E-rare and Rare 2030 expert panel and a patient expert at EMA and IMI. One of her main interests is translational research in skeletal dysplasias and now. ORCID ID: 0000-0001-8963-4736,
Inês Alves, DVM
ANDO Portugal President / ERN BOND ePAG and SC member / COMP EMA member
Other speakers in 2022
Borislav Borissov, Assoc. Prof. Dr., MBA, DSCI
Ideologist and Managing Director at Biotech Atelier
Managing Director of Prescriptia Ltd., Chairman of the Management Board of Bulgarian Association of Clinical Research
Mats Hansson
Senior Professor of Biomedical Ethics at the Centre for Research Ethics & Bioethics, Uppsala University
Coordinator and Academic Lead of the IMI-project PREFER (2016-2022)
Magdalena Daccord
Chief Executive
FH Europe, the European Network of patient organizations advocating for people living with familial hyperlipidaemias